Integra Lifesciences (NASDAQ:IART) was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Friday.

A number of other research firms have also weighed in on IART. Barclays reissued an “equal weight” rating and set a $53.00 target price (up previously from $47.00) on shares of Integra Lifesciences in a research report on Tuesday, September 12th. Jefferies Group reissued a “buy” rating on shares of Integra Lifesciences in a research report on Sunday, September 10th. Oppenheimer reissued a “buy” rating and set a $60.00 target price on shares of Integra Lifesciences in a research report on Monday, September 18th. Finally, Zacks Investment Research lowered shares of Integra Lifesciences from a “buy” rating to a “hold” rating in a research report on Monday, October 9th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $53.64.

Shares of Integra Lifesciences (NASDAQ:IART) opened at $46.55 on Friday. The company has a quick ratio of 3.39, a current ratio of 4.49 and a debt-to-equity ratio of 1.26. Integra Lifesciences has a 52 week low of $40.51 and a 52 week high of $56.42. The stock has a market cap of $3,701.78, a price-to-earnings ratio of 76.31, a P/E/G ratio of 1.57 and a beta of 0.65.

Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings data on Thursday, October 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.02). The business had revenue of $278.83 million during the quarter, compared to analyst estimates of $286.00 million. Integra Lifesciences had a net margin of 4.52% and a return on equity of 16.35%. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.93 EPS. research analysts forecast that Integra Lifesciences will post 1.85 earnings per share for the current year.

In other news, VP Richard D. Gorelick sold 1,500 shares of the company’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total transaction of $70,785.00. Following the completion of the transaction, the vice president now owns 21,665 shares of the company’s stock, valued at $1,022,371.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Barbara B. Hill acquired 10,768 shares of the business’s stock in a transaction dated Tuesday, October 31st. The shares were bought at an average cost of $46.66 per share, with a total value of $502,434.88. Following the transaction, the director now directly owns 55,540 shares of the company’s stock, valued at approximately $2,591,496.40. The disclosure for this purchase can be found here. 21.50% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Prudential Financial Inc. increased its stake in Integra Lifesciences by 3.3% in the third quarter. Prudential Financial Inc. now owns 105,836 shares of the life sciences company’s stock valued at $5,343,000 after acquiring an additional 3,340 shares during the period. Jennison Associates LLC increased its stake in Integra Lifesciences by 48.3% in the third quarter. Jennison Associates LLC now owns 1,034,702 shares of the life sciences company’s stock valued at $52,232,000 after acquiring an additional 336,930 shares during the period. Ameriprise Financial Inc. increased its stake in Integra Lifesciences by 2.9% in the second quarter. Ameriprise Financial Inc. now owns 434,993 shares of the life sciences company’s stock valued at $23,709,000 after acquiring an additional 12,212 shares during the period. Royal Bank of Canada increased its stake in Integra Lifesciences by 21.4% in the second quarter. Royal Bank of Canada now owns 1,072,799 shares of the life sciences company’s stock valued at $58,477,000 after acquiring an additional 188,893 shares during the period. Finally, First Trust Advisors LP increased its stake in Integra Lifesciences by 216.1% in the third quarter. First Trust Advisors LP now owns 51,084 shares of the life sciences company’s stock valued at $2,579,000 after acquiring an additional 34,925 shares during the period. 87.58% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/06/integra-lifesciences-iart-downgraded-to-strong-sell-at-bidaskclub.html.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.